At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 357 enrolled
Drug / intervention
OROS MPH +3 moredrug
Likely dose
OROS MPH 18 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Placebo Controlled Double-Blind, Parallel Group, Individualizing Dosing Study Optimizing Treatment of Adults With Attention Deficit Hyperactivity Disorder to an Effective Response With OROS Methylphenidate
Ortho-McNeil Janssen Scientific Affairs, LLC·interventional·Posted Jul 10, 2009·Updated Jul 30, 2013
In Brief
A Phase 4 clinical trial evaluating OROS MPH, Placebo, and 2 other interventions for Attention Deficit Disorder With Hyperactivity. Completed, enrolled 357 participants.
Detailed Summary
The purpose of this study is to compare the ADHD symptom response of adults with ADHD treated with OROS MPH to those treated with placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2009
First PostedJul 2009
Primary CompletionFeb 2010
TodayJul 2026
First PostedJul 10, 2009
Enrollment StartJul 1, 2009
Primary CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.0 years ago
Interventions
OROS MPHdrug
Optimal Patient Dose (18 mg-72 mg) once daily for 6 weeks
Placebodrug
Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily for 6 weeks
OROS MPH Tabletsdrug
Optimal Patient Dose (18 mg-72 mg) once daily by mouth for 6 weeks
Placebo Tabletsdrug
Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily by mouth for 6 weeks